Table 1.

Demographics of enrolled NPC patients.

GENDER
Male	112 (74.7%)
Female	38 (25.3%)
AGE
Median	52.0
Range	22.0–80.0
T STAGE
T1	11 (7.3%)
T2	23 (15.3%)
T3	79 (52.7%)
T4	37 (24.7%)
N STAGE
N0	8 (5.3%)
N1	41 (27.3%)
N2	84 (56.0%)
N3	17 (11.3%)
TREATMENT OPTIONS
Induction chemotherapy + concurrent chemoradiotherapy	53 (35.3%)
Radiotherapy or concurrent chemoradiotherapy	97 (64.7%)
CTVp1 VOLUME (ml)
Range	173–741
Mean	264 ± 80

NPC, nasopharyngeal carcinoma; CTVp1, primary tumor clinical target volume.